Skip to main content
. Author manuscript; available in PMC: 2017 Feb 11.
Published in final edited form as: Nature. 2016 Aug 11;536(7615):184–189. doi: 10.1038/nature18943

Figure 1. TORC1 inhibition induces the proteasome assembly chaperone Adc17 and increases proteasome levels.

Figure 1

a-c, Immunoblots of lysates from cells treated ± 5 µg/ml tunicamycin (Tm) for 4 hours. d, Immunoblots of lysates from cells treated ± 0.2 µg/ml rapamycin (Rapa) for 4 hours. e, Immunoblots of cell lysates after treatment ± 5 µg/ml Tm or 0.2 µg/ml Rapa for 4 hours. f, Cartoon depicting the relationship between Sfp1, TORC1 and Adc17. g, Immunoblots from cells cultured at 30 or 37°C for 4 hours. h, Native-PAGE (4.2%) of yeast extracts from cells treated with 5 µg/ml Tm or 0.2 µg/ml Rapa, revealed with the fluorogenic substrate Suc-LLVY-AMC and by immunoblots. i, Quantification of the 26S proteasome activity (RP-CP and RP2-CP) in four independent experiments such as the one shown in (h). Data are means ± SD; n = 4 biological replicates. ***P≤0.001; n.s., not significant (one-way ANOVA).

HHS Vulnerability Disclosure